0

Close
 
Upcoming Allied Market Research
2023
Histone Deacetylase Inhibitors Market

Histone Deacetylase Inhibitors Market

by CLASS (Class I HDACs, Class II HDACs, Class III HDACs) and by APPLICATION (Cancer, Central Nervous System Disorders, Other Diseases): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A00003
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Histone Deacetylase Inhibitors Market

Request Now !

The Histone deactylase inhibitor (HDAC) is a molecule that consists of different compounds that form a group of anticancer agents. The parent epigenetic market of HDAC is expected to grow at a CAGR of around 30% worldwide. The factors driving this market are increase in cancer incidences, ongoing research and development for the treatment of cancer, other diseases, and the need to improve the effectiveness of new therapies. The major limitation of this market is reimbursement and uncertainty issues. The opportunities for this market are increase in collaborations and huge investments in manufacturing which will ensure significant growth.

Key market players of this market are, Celgene, Acetylon Pharmaceuticals, Celleron Therapeutics, Envivo Pharmaceuticals, Novartis, Merck & Co., and Pfizer.

KEY BENEFITS:

  • The report provides Market attractiveness analysis for the most attractive geographical region worldwide, and considers factors responsible for rapid growth in the regions. 
  • Various economic factors which are significant in determining market trend, buying decisions and market attractiveness are been analyzed for market estimation and forecasting
  • The report evaluates the key factors of drivers, restraints and opportunities enabling strategic decision making with perceptive to identify potential market.
  • The study also discusses various environmental and regulatory factors critical for the market growth.
  • The analysis will support stakeholders such as manufacturers and distributors in identifying and capturing markets with high potential.

 Histone Deacetylase Inhibitors Market Report Highlights

Aspects Details
By CLASS
  • Class I HDACs
  • Class II HDACs
  • Class III HDACs
By APPLICATION
  • Cancer
  • Central Nervous System Disorders
  • Other Diseases
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players GNT Biotech and Medicals Corp., Eisai Co. Ltd., Envivo Pharmaceuticals, Novartis, Bristol Myers Squibb Co., Celleron Therapeutics, Acetylon Pharmaceuticals, Pfizer, Merck and Co., Celgene
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: HISTONE DEACETYLASE INHIBITORS MARKET, BY CLASS

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Class

    • 4.2. Class I HDACs

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Class II HDACs

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Class III HDACs

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: HISTONE DEACETYLASE INHIBITORS MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Cancer

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Central Nervous System Disorders

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Other Diseases

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: HISTONE DEACETYLASE INHIBITORS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Class

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Histone Deacetylase Inhibitors Market

        • 6.2.5.1. Market Size and Forecast, By Class
        • 6.2.5.2. Market Size and Forecast, By Application

      • 6.2.6. Canada Histone Deacetylase Inhibitors Market

        • 6.2.6.1. Market Size and Forecast, By Class
        • 6.2.6.2. Market Size and Forecast, By Application

      • 6.2.7. Mexico Histone Deacetylase Inhibitors Market

        • 6.2.7.1. Market Size and Forecast, By Class
        • 6.2.7.2. Market Size and Forecast, By Application

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Class

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Histone Deacetylase Inhibitors Market

        • 6.3.5.1. Market Size and Forecast, By Class
        • 6.3.5.2. Market Size and Forecast, By Application

      • 6.3.6. Germany Histone Deacetylase Inhibitors Market

        • 6.3.6.1. Market Size and Forecast, By Class
        • 6.3.6.2. Market Size and Forecast, By Application

      • 6.3.7. Italy Histone Deacetylase Inhibitors Market

        • 6.3.7.1. Market Size and Forecast, By Class
        • 6.3.7.2. Market Size and Forecast, By Application

      • 6.3.8. Spain Histone Deacetylase Inhibitors Market

        • 6.3.8.1. Market Size and Forecast, By Class
        • 6.3.8.2. Market Size and Forecast, By Application

      • 6.3.9. UK Histone Deacetylase Inhibitors Market

        • 6.3.9.1. Market Size and Forecast, By Class
        • 6.3.9.2. Market Size and Forecast, By Application

      • 6.3.10. Russia Histone Deacetylase Inhibitors Market

        • 6.3.10.1. Market Size and Forecast, By Class
        • 6.3.10.2. Market Size and Forecast, By Application

      • 6.3.11. Rest Of Europe Histone Deacetylase Inhibitors Market

        • 6.3.11.1. Market Size and Forecast, By Class
        • 6.3.11.2. Market Size and Forecast, By Application

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Class

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Histone Deacetylase Inhibitors Market

        • 6.4.5.1. Market Size and Forecast, By Class
        • 6.4.5.2. Market Size and Forecast, By Application

      • 6.4.6. Japan Histone Deacetylase Inhibitors Market

        • 6.4.6.1. Market Size and Forecast, By Class
        • 6.4.6.2. Market Size and Forecast, By Application

      • 6.4.7. India Histone Deacetylase Inhibitors Market

        • 6.4.7.1. Market Size and Forecast, By Class
        • 6.4.7.2. Market Size and Forecast, By Application

      • 6.4.8. South Korea Histone Deacetylase Inhibitors Market

        • 6.4.8.1. Market Size and Forecast, By Class
        • 6.4.8.2. Market Size and Forecast, By Application

      • 6.4.9. Australia Histone Deacetylase Inhibitors Market

        • 6.4.9.1. Market Size and Forecast, By Class
        • 6.4.9.2. Market Size and Forecast, By Application

      • 6.4.10. Thailand Histone Deacetylase Inhibitors Market

        • 6.4.10.1. Market Size and Forecast, By Class
        • 6.4.10.2. Market Size and Forecast, By Application

      • 6.4.11. Malaysia Histone Deacetylase Inhibitors Market

        • 6.4.11.1. Market Size and Forecast, By Class
        • 6.4.11.2. Market Size and Forecast, By Application

      • 6.4.12. Indonesia Histone Deacetylase Inhibitors Market

        • 6.4.12.1. Market Size and Forecast, By Class
        • 6.4.12.2. Market Size and Forecast, By Application

      • 6.4.13. Rest of Asia Pacific Histone Deacetylase Inhibitors Market

        • 6.4.13.1. Market Size and Forecast, By Class
        • 6.4.13.2. Market Size and Forecast, By Application

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Class

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Histone Deacetylase Inhibitors Market

        • 6.5.5.1. Market Size and Forecast, By Class
        • 6.5.5.2. Market Size and Forecast, By Application

      • 6.5.6. South Africa Histone Deacetylase Inhibitors Market

        • 6.5.6.1. Market Size and Forecast, By Class
        • 6.5.6.2. Market Size and Forecast, By Application

      • 6.5.7. Saudi Arabia Histone Deacetylase Inhibitors Market

        • 6.5.7.1. Market Size and Forecast, By Class
        • 6.5.7.2. Market Size and Forecast, By Application

      • 6.5.8. UAE Histone Deacetylase Inhibitors Market

        • 6.5.8.1. Market Size and Forecast, By Class
        • 6.5.8.2. Market Size and Forecast, By Application

      • 6.5.9. Argentina Histone Deacetylase Inhibitors Market

        • 6.5.9.1. Market Size and Forecast, By Class
        • 6.5.9.2. Market Size and Forecast, By Application

      • 6.5.10. Rest of LAMEA Histone Deacetylase Inhibitors Market

        • 6.5.10.1. Market Size and Forecast, By Class
        • 6.5.10.2. Market Size and Forecast, By Application

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Celgene

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Acetylon Pharmaceuticals

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Celleron Therapeutics

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Envivo Pharmaceuticals

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Novartis

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Merck And Co.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Pfizer

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. GNT Biotech And Medicals Corp.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Eisai Co. Ltd.

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Bristol Myers Squibb Co.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET FOR CLASS I HDACS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET FOR CLASS II HDACS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET FOR CLASS III HDACS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET FOR CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET FOR OTHER DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 13. U.S. HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 14. U.S. HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 15. CANADA HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 16. CANADA HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 17. MEXICO HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 18. MEXICO HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 19. EUROPE HISTONE DEACETYLASE INHIBITORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 22. FRANCE HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 23. FRANCE HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 24. GERMANY HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 25. GERMANY HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. ITALY HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 27. ITALY HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 28. SPAIN HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 29. SPAIN HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 30. UK HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 31. UK HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 32. RUSSIA HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 33. RUSSIA HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 34. REST OF EUROPE HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 35. REST OF EUROPE HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 38. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 39. CHINA HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 40. CHINA HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 41. JAPAN HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 42. JAPAN HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 43. INDIA HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 44. INDIA HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. SOUTH KOREA HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 46. SOUTH KOREA HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 47. AUSTRALIA HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 48. AUSTRALIA HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 49. THAILAND HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 50. THAILAND HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. MALAYSIA HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 52. MALAYSIA HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 53. INDONESIA HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 54. INDONESIA HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 57. LAMEA HISTONE DEACETYLASE INHIBITORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 58. LAMEA HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 59. LAMEA HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 60. BRAZIL HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 61. BRAZIL HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 62. SOUTH AFRICA HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 63. SOUTH AFRICA HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. SAUDI ARABIA HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 65. SAUDI ARABIA HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 66. UAE HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 67. UAE HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 68. ARGENTINA HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 69. ARGENTINA HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 70. REST OF LAMEA HISTONE DEACETYLASE INHIBITORS, BY CLASS, 2022-2032 ($MILLION)
  • TABLE 71. REST OF LAMEA HISTONE DEACETYLASE INHIBITORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 72. CELGENE: KEY EXECUTIVES
  • TABLE 73. CELGENE: COMPANY SNAPSHOT
  • TABLE 74. CELGENE: OPERATING SEGMENTS
  • TABLE 75. CELGENE: PRODUCT PORTFOLIO
  • TABLE 76. CELGENE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 77. ACETYLON PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 78. ACETYLON PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 79. ACETYLON PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 80. ACETYLON PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 81. ACETYLON PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 82. CELLERON THERAPEUTICS: KEY EXECUTIVES
  • TABLE 83. CELLERON THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 84. CELLERON THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 85. CELLERON THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 86. CELLERON THERAPEUTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 87. ENVIVO PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 88. ENVIVO PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 89. ENVIVO PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 90. ENVIVO PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 91. ENVIVO PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 92. NOVARTIS: KEY EXECUTIVES
  • TABLE 93. NOVARTIS: COMPANY SNAPSHOT
  • TABLE 94. NOVARTIS: OPERATING SEGMENTS
  • TABLE 95. NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 96. NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 97. MERCK AND CO.: KEY EXECUTIVES
  • TABLE 98. MERCK AND CO.: COMPANY SNAPSHOT
  • TABLE 99. MERCK AND CO.: OPERATING SEGMENTS
  • TABLE 100. MERCK AND CO.: PRODUCT PORTFOLIO
  • TABLE 101. MERCK AND CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 102. PFIZER: KEY EXECUTIVES
  • TABLE 103. PFIZER: COMPANY SNAPSHOT
  • TABLE 104. PFIZER: OPERATING SEGMENTS
  • TABLE 105. PFIZER: PRODUCT PORTFOLIO
  • TABLE 106. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 107. GNT BIOTECH AND MEDICALS CORP.: KEY EXECUTIVES
  • TABLE 108. GNT BIOTECH AND MEDICALS CORP.: COMPANY SNAPSHOT
  • TABLE 109. GNT BIOTECH AND MEDICALS CORP.: OPERATING SEGMENTS
  • TABLE 110. GNT BIOTECH AND MEDICALS CORP.: PRODUCT PORTFOLIO
  • TABLE 111. GNT BIOTECH AND MEDICALS CORP.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. EISAI CO. LTD.: KEY EXECUTIVES
  • TABLE 113. EISAI CO. LTD.: COMPANY SNAPSHOT
  • TABLE 114. EISAI CO. LTD.: OPERATING SEGMENTS
  • TABLE 115. EISAI CO. LTD.: PRODUCT PORTFOLIO
  • TABLE 116. EISAI CO. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. BRISTOL MYERS SQUIBB CO.: KEY EXECUTIVES
  • TABLE 118. BRISTOL MYERS SQUIBB CO.: COMPANY SNAPSHOT
  • TABLE 119. BRISTOL MYERS SQUIBB CO.: OPERATING SEGMENTS
  • TABLE 120. BRISTOL MYERS SQUIBB CO.: PRODUCT PORTFOLIO
  • TABLE 121. BRISTOL MYERS SQUIBB CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET
  • FIGURE 3. SEGMENTATION HISTONE DEACETYLASE INHIBITORS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN HISTONE DEACETYLASE INHIBITORS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHISTONE DEACETYLASE INHIBITORS MARKET
  • FIGURE 11. HISTONE DEACETYLASE INHIBITORS MARKET SEGMENTATION, BY BY CLASS
  • FIGURE 12. HISTONE DEACETYLASE INHIBITORS MARKET FOR CLASS I HDACS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. HISTONE DEACETYLASE INHIBITORS MARKET FOR CLASS II HDACS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. HISTONE DEACETYLASE INHIBITORS MARKET FOR CLASS III HDACS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. HISTONE DEACETYLASE INHIBITORS MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 16. HISTONE DEACETYLASE INHIBITORS MARKET FOR CANCER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. HISTONE DEACETYLASE INHIBITORS MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. HISTONE DEACETYLASE INHIBITORS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 20. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 21. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 22. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 23. COMPETITIVE DASHBOARD
  • FIGURE 24. COMPETITIVE HEATMAP: HISTONE DEACETYLASE INHIBITORS MARKET
  • FIGURE 25. Top player positioning, 2022
  • FIGURE 26. CELGENE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 27. CELGENE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 28. CELGENE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 29. ACETYLON PHARMACEUTICALS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 30. ACETYLON PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 31. ACETYLON PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 32. CELLERON THERAPEUTICS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. CELLERON THERAPEUTICS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. CELLERON THERAPEUTICS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. ENVIVO PHARMACEUTICALS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. ENVIVO PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. ENVIVO PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. NOVARTIS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. NOVARTIS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. NOVARTIS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. MERCK AND CO.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. MERCK AND CO.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. MERCK AND CO.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. PFIZER: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. PFIZER: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. PFIZER: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. GNT BIOTECH AND MEDICALS CORP.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. GNT BIOTECH AND MEDICALS CORP.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. GNT BIOTECH AND MEDICALS CORP.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. EISAI CO. LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. EISAI CO. LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. EISAI CO. LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. BRISTOL MYERS SQUIBB CO.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. BRISTOL MYERS SQUIBB CO.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. BRISTOL MYERS SQUIBB CO.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Histone Deacetylase Inhibitors Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers